Reentry Program for HIV/AIDS

(THRASHER Trial)

Recruiting in Palo Alto (17 mi)

Overseen by Anne Spaulding, MD, MPH

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Emory University

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study is testing a behavioral intervention with a case manager/peer navigator team pairing with clients to deliver transition planning services. The interactions help clients recognize and use their strengths. The goal is to see if this approach improves clients' ability to access healthcare and drug treatment after being released from jail.

Research Team

Anne Spaulding, MD, MPH

Principal Investigator

Emory University

Eligibility Criteria

The THRASHER trial is for individuals with HIV/AIDS who are transitioning out of jail. Participants should be willing to work with a case manager/peer navigator team and engage in transition planning services aimed at improving access to healthcare and drug treatment post-release.

Inclusion Criteria

I am living with HIV or at high risk of contracting it.

I understand the study and agree to participate.

Willing to participate in study activities

Exclusion Criteria

Admission to a prison facility (Federal or state)

I understand the consent form and do not have severe mental health issues.

Treatment Details

Interventions

• THRASHER (Behavioral Intervention)

Trial Overview This study evaluates the SUCCESS-E behavioral intervention, which pairs clients with support teams to leverage their strengths during reentry into society. It aims to determine if this method enhances healthcare and drug treatment accessibility after incarceration.

Participant Groups

Group I: SUCCESS-E Experimental Treatment 1 Intervention

Participants with SUD, living with HIV or at high risk for seroconversion, will be placed in strength-based case management, delivered by a case manager and peer navigators, both in jail and in the community, leading to linkage and retention in healthcare and SUD treatment.

Group II: Key informant interviews (KII) Experimental Treatment 1 Intervention

Jail staff and community members willing to participate in Key Informant Interviews (KIIs)

Group III: Control Group Experimental Treatment 1 Intervention

Participants not placed in the intervention group will have healthcare services inform them of possible medical homes for HIV/PrEP care and a list of referral sites for follow-up SUD care.

Who Is Running the Clinical Trial?

Emory University

Lead Sponsor

Trials

1,735

Recruited

2,605,000+

Dr. R. Donald Harvey

Emory University

Chief Medical Officer

MD from Emory University School of Medicine

Dr. George Painter

Emory University

Chief Executive Officer since 2013

PhD in Synthetic Organic Chemistry from Emory University

National Institute on Drug Abuse (NIDA)

Collaborator

Trials

2,658

Recruited

3,409,000+

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Executive Officer since 2003

MD from National Autonomous University of Mexico

Dr. Nora Volkow

National Institute on Drug Abuse (NIDA)

Chief Medical Officer since 2003

MD from National Autonomous University of Mexico